A Study of AL58805 in Patients With Advanced Tumors

NCT ID: NCT07179081

Last Updated: 2025-09-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-20
• Study Completion Date: 2026-01-26

Brief Summary

This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.

Conditions

Advanced Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

AL58805

20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；

Group Type: EXPERIMENTAL

AL58805

Intervention Type: DRUG

Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）

Interventions

AL58805

Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Subjects must meet all the following criteria to be eligible:

1. Patients with histologically or cytologically confirmed advanced tumors (including but not limited to lymphoma, colorectal cancer, breast cancer, pancreatic cancer, lung cancer, head and neck cancer, bladder cancer, cholangiocarcinoma) who lack effective standard treatment options or have failed conventional standard treatments (due to disease progression or intolerable toxicity).

2. Previous treatment with cytotoxic chemotherapy, with at least 4 weeks between the end of chemotherapy and enrollment, and recovery from previous chemotherapy toxicities to ≤ Grade 1 (except alopecia).

3. Must have measurable lesions according to RECIST 1.1 criteria.

4. Major organ function: Absolute neutrophil count (ANC) ≥1.5 × 10^9/L (1500/mm3), platelets ≥75 × 10^9/L, hemoglobin ≥9g/dL. Serum total bilirubin ≤2 × upper limit of normal (ULN). Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min. For patients without liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with liver metastases, ALT and AST ≤5 × ULN. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal.

5. Age ≥18 years; ECOG performance status (PS) 0 or 1.

6. Expected survival time of at least 12 weeks.

7. No malabsorption or other gastrointestinal diseases affecting drug absorption.

8. For women of childbearing potential: Negative pregnancy test before treatment and use of medically approved contraception during treatment and for 3 months after treatment ends. Must be non-lactating.

9. For male subjects: Surgical sterilization or use of medically approved contraception during treatment and for 3 months after treatment ends.

Ability to understand and sign informed consent.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded:

1. Known allergy to the investigational drug or drugs with similar chemical structures.

2. Use of unapproved drugs or other investigational drugs within 30 days before enrollment.

3. Status of the organ systems:

Current symptomatic brain metastases or leptomeningeal metastases, or central nervous system (CNS) metastases with uncontrolled symptoms within 8 weeks of first dose.

Uncontrolled hypertension requiring multiple medications (Grade 2 or higher). Acute myocardial infarction within 6 months. Current arrhythmias (e.g., long QT syndrome, Bazett's corrected QTc ≥480 ms). NYHA Class III or IV heart failure. Poorly controlled diabetes. Any unstable systemic disease (including active infection, angina, hepatic, renal, or metabolic diseases).

Presence of ascites or pleural effusion (CTCAE 5.0 ≥ Grade 2). Persistent diarrhea (average watery stools ≥1 per day). History of definite neurological or psychiatric disorders (e.g., epilepsy, dementia, mood disorders).

Patients with active/venous thrombosis events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism.

5. Previous treatment with the investigational drug.

7. Concurrent other anti-tumor treatments. Other conditions deemed unsuitable by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Advenchen Laboratories Nanjing Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dongfang Li

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Yongchang Zhang

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Locations

Hunan Cancer Hospital

Changsha, Hunan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Li Sha Qi

Role: CONTACT

qilisha@advenchen.com.cn

025-52896159

Facility Contacts

Hongkun Cai

Role: primary

hnszlyy_irb@163.com

0731-89762695

Other Identifiers

AL58805-CN-001B

Identifier Type: -

Identifier Source: org_study_id